证券代码：688166 证券简称：博瑞医药 公告编号：2025-013 博瑞生物医药（苏州）股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 拟投资基金名称：南京弘晖维泰创业投资基金合伙企业（有限合伙） （以 下简称"弘晖维泰创投基金"、"合伙企业"或"本合伙企业"） ? 基金投资方向，与上市公司主营业务相关性：弘晖维泰创投基金主要投 资于医药器械领域的早期项目，重点关注生命科学领域最前沿的技术创新和转 化。本次投资有利于公司在早期创新药械领域和生命科学前沿领域成果转化的布 局，与公司的产品研发管线有潜在协同效应。 ? 拟投资金额：弘晖维泰创投基金拟定募集资金规模为人民币 30,000 万元， 博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"）拟作 为有限合伙人出资人民币 2,000 万元，认缴出资比例为 6.70%。 ? 关联关系说明：南京瑞弘熠鑫企业管理合伙企业（有限合伙）为弘晖维 泰创投基金的普通合伙人，监事会主席何幸先生担任南京瑞弘熠鑫企业管理合伙 企业（有限合伙）投 ...

Summary of Key Points Core Viewpoint - The company, BrightGene (Suzhou) Pharmaceutical Co., Ltd., plans to apply for a comprehensive credit limit of up to 3 billion RMB for the year 2025 from banks and financial leasing companies, with mutual guarantees among its subsidiaries [1][2]. Group 1: Credit Application and Guarantee - The total credit limit proposed for 2025 is not to exceed 3 billion RMB, which will include various types of loans and financial services [1][2]. - As of December 31, 2024, the total amount of guarantees provided by the company to its subsidiaries is 1,139.63 million RMB, accounting for 47.59% of the company's audited net assets and 22.07% of its total audited assets for the year 2024 [1][20]. - The proposed guarantees do not involve any counter-guarantees [1]. Group 2: Shareholder Meeting and Authorization - The proposal for the credit application and guarantees will be submitted for approval at the company's 2024 annual general meeting [2]. - The shareholders will authorize the legal representative or their delegate to negotiate specific credit business types, terms, rates, and to sign relevant contracts and agreements [2]. Group 3: Subsidiary Information - BrightGene (Suzhou) Pharmaceutical Co., Ltd. holds an 80% stake in BrightGene Pharmaceutical (Suzhou) Co., Ltd., which has total assets of 571.92 million RMB and net assets of 277.19 million RMB as of December 31, 2023 [2][3]. - The company also has several subsidiaries, including Suzhou Guangtai Biotechnology Co., Ltd. and BrightGene International (HK) Limited, with varying financial metrics and operational scopes [3][4][5]. Group 4: Financial Health and Performance - The financial performance of the subsidiaries shows a mix of revenues and losses, with some subsidiaries reporting zero revenue and negative net profits for 2023 and projected for 2024 [3][4][5][10][11]. - The overall financial health of the company and its subsidiaries indicates a need for the proposed credit to support ongoing operations and growth [1][20]. Group 5: Board and Regulatory Approval - The board of directors approved the proposal with a unanimous vote, indicating strong internal support for the credit application and guarantee strategy [20]. - The proposal complies with relevant regulations and has undergone necessary approval processes as per the Shanghai Stock Exchange rules [20].

Core Viewpoint - 博瑞生物医药（苏州）股份有限公司 plans to conduct forward foreign exchange trading to mitigate risks associated with foreign exchange rate and interest rate fluctuations, with a maximum transaction amount not exceeding the equivalent of 150 million USD [1][2][4]. Summary by Sections 1. Transaction Overview - The company aims to engage in forward foreign exchange trading, including forward contracts and foreign exchange options, primarily for hedging purposes to reduce the impact of exchange rate and interest rate fluctuations on its operating performance [1][2]. - The maximum transaction amount for the forward foreign exchange trading is set at 150 million USD, with the highest contract value on any trading day not exceeding this amount [2]. 2. Funding Sources - The funding for the forward foreign exchange trading will primarily come from the company's own funds, without involving raised funds or bank credit [2]. 3. Trading Methods - The trading methods include, but are not limited to, foreign currency forward contracts and foreign exchange options, which allow the company to lock in exchange rates for future transactions [2][3]. 4. Trading Duration - The authorization period for these transactions is set for 12 months from the date of board approval, with the ability to roll over the authorized amount within this timeframe [4]. 5. Risk Analysis and Control Measures - The company adheres to principles of legality, prudence, safety, and effectiveness in its forward foreign exchange trading, avoiding speculative activities [4][5]. - A comprehensive internal control system has been established to manage risks associated with foreign exchange derivatives, including regular assessments and reporting to management [5]. 6. Impact on the Company - Engaging in forward foreign exchange trading is based on normal business operations and aims to enhance the company's ability to manage exchange rate risks without affecting normal cash flow or business operations [6]. 7. Compliance and Review - The proposed foreign exchange derivative trading has been reviewed and approved by the company's board and supervisory committee, complying with relevant laws and regulations [6].

Core Viewpoint - The company has released its 2024 and 2025 action plans focusing on enhancing quality, efficiency, and returns to shareholders, while emphasizing innovation in drug development and market expansion [1][2][3]. Group 1: Business Focus and Product Development - The company is an innovative pharmaceutical enterprise engaged in international competition, focusing on the development of generic drugs, difficult-to-generate drugs, and original new drugs to meet unmet clinical needs globally [1][2]. - Key therapeutic areas include antiviral, antifungal, immunosuppressive, respiratory, anti-tumor, and metabolic diseases, with core products such as Entecavir and Oseltamivir in the antiviral category [1][2]. - The company has established several core drug research and development technology platforms, including fermentation semi-synthesis and drug-device combination platforms [2]. Group 2: Financial Performance - In 2024, the company's net profit attributable to shareholders was 189.17 million yuan, a decrease of 6.57% year-on-year, while the net profit after deducting non-recurring gains and losses was 180.51 million yuan, down 3.12% year-on-year [2][3]. - Revenue from drug sales, technology income, and profit-sharing income are the main components of the company's operating income [2]. Group 3: Research and Development - The company increased its R&D investment to 311.79 million yuan in 2024, a year-on-year increase, with 62.78% of this investment directed towards innovative drugs and inhalation formulations [3][4]. - The innovative drug BGM0504, a dual agonist for GLP-1 and GIP receptors, is in phase III clinical trials for diabetes treatment and weight loss [4][8]. Group 4: Future Action Plans - The company aims to address unmet clinical needs by focusing on high-tech and high-clinical-value products, continuing its strategy of combining high-end generics with original new drugs [5][6]. - Plans include developing differentiated GLP-1 drugs and exploring new administration methods to enhance patient compliance [5][6]. Group 5: Global Market Expansion - The company is actively participating in global competition, with products certified by GMP in multiple regions, including China, the US, and the EU, and has achieved sales in over 40 countries [6][9]. - The company plans to expand its market presence in emerging markets along the "Belt and Road" initiative while enhancing its product portfolio [9]. Group 6: Governance and Investor Relations - The company has established a governance structure to ensure compliance and high-quality development, including various committees to oversee operations [12][13]. - The company emphasizes investor communication, conducting regular meetings and utilizing various platforms to enhance transparency and investor confidence [14][16]. Group 7: Shareholder Returns - The company has maintained a stable dividend policy, with cumulative cash dividends of 206 million yuan from 2019 to 2023, and plans to distribute 40.52 million yuan in cash dividends for 2024 [17][18]. - The controlling shareholders have committed to not reducing their holdings for six months to enhance investor confidence [18].

往 企业 经营性 控股股东、实际 | 关于博瑞生物医药（苏州）股份有限公司 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用及其他关联资金往来情况 | | | | | | | | | | | | 汇总表的专项审计报告 | | | | | | | | | | | | 目 录 | | | | | | | | | | | | 委托单位：博瑞生物医药（苏州）股份有限公司 | | | | | | | | | | | | 审计单位：公证天业会计师事务所（特殊普通合伙） | | | | | | | | | | | | 联系电话：86 (510)68798988 | | | | | | | | | | | | 附表 2 | | | | | | | | | | | | | | | | 关于博瑞生物医药（苏州）股份有限公司 | | | | | | | | | | | | | 2024 年期 | | | | 2024 年度 | 单位：万元 2024 年期 | | 占用方与上市 非经 ...

博瑞生物医药（苏州）股份有限公司 董事会审计委员会对会计师事务所 2024 年度履行监督职责 情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》等相关法律法规以及 《博瑞生物医药（苏州）股份有限公司章程》等相关规章制度的要求，博瑞生物 医药（苏州）股份有限公司（以下简称"公司"或"本公司"）董事会审计委员 会本着勤勉尽责的原则，认真履行了审计监督职责。现本委员会对会计师事务所 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 公证天业会计师事务所（特殊普通合伙）（以下简称"公证天业"）成立于 市太湖新城嘉业财富中心 5-1001 室。公证天业已取得江苏省财政厅颁发的会计 师事务所执业证书，是我国较早从事证券业务的会计师事务所之一，长期从事证 券服务业务。2020 年 11 月，财政部、证监会公布《从事证券服务业务会计师事 务所备案名单及基本信息》，公证天业成为从事证券服务业务首批备案的会计师 事务所。 公证天业在资质等方面合规有效，履职能够保持独立性，勤勉尽责，公允表 达意见。在执行审计工作的过程中，公证天业根 ...

Core Viewpoint - The independent director of Borui Biopharmaceuticals (Suzhou) Co., Ltd. has reported on their performance during the 2024 term, emphasizing adherence to legal regulations and commitment to protecting the interests of the company and its shareholders, particularly minority shareholders [1][2]. Group 1: Independent Director's Basic Information - The independent director, Ruyi He, has a strong professional background, including roles at various prestigious institutions and currently serves as the Chief Scientist at Guotou Innovation Medical Health [1]. - Ruyi He maintains independence by not holding any other positions within the company or its major shareholders, ensuring objective judgment [1]. Group 2: Attendance and Participation - Throughout the term, the independent director attended all required meetings, including board meetings and special committees, demonstrating diligence and responsibility [2]. - The independent director voted in favor of all proposals during the meetings held in the reporting period [2]. Group 3: Communication and Company Support - The independent director maintained effective communication with the company's board and management, providing insights on strategic planning and industry trends [4]. - The company provided necessary materials and timely responses to inquiries, facilitating the independent director's responsibilities [4]. Group 4: Exercise of Independent Director Powers - During the 2024 term, the independent director did not exercise specific powers such as proposing the hiring of external consultants or calling for extraordinary shareholder meetings [4]. Group 5: Focus on Key Issues - The independent director reviewed related party transactions, confirming their compliance with the company's operational needs and fairness to all shareholders [5]. - The independent director participated in the nomination and review of candidates for the board, ensuring thorough evaluation of qualifications [6]. Group 6: Overall Evaluation and Recommendations - The independent director's contributions were noted as significant in protecting the interests of all shareholders, particularly minority shareholders, and promoting sustainable company development [6].

博瑞生物医药（苏州）股份有限公司 舆情管理制度 第一章 总则 第一条 为提高博瑞生物医药（苏州）股份有限公司（以下简称"公司"）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对 公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据相关法律法规、规范性文件和《博瑞生物医药（苏州）股份有限公司章程》 （以下简称"公司章程"）等规定，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同应对。 第四条 公司舆情管理工作由公司董事会统一领导和管理，董事长作为第一 责任人，负责领导各类舆情处理工作。必要时可成立舆情管理应急小组，由董事 长任组长，董事会秘书任副组长，其他高级管理人员或 ...

Core Viewpoint - The company plans to distribute a cash dividend of 0.096 CNY per share, amounting to a total of approximately 40.52 million CNY, which represents 21.42% of the net profit attributable to shareholders for the year [1][2][3] Profit Distribution Plan - The profit distribution is based on the total share capital registered on the equity distribution record date, with a proposed cash dividend of 0.96 CNY for every 10 shares held [1][2] - The total number of shares eligible for distribution is 422,106,055, after excluding 363,461 shares held in the company's repurchase account [1][2] - The cash dividend distribution plan is subject to approval at the company's 2024 annual general meeting [2][8] Financial Performance - For the reporting period, the company achieved a revenue of 1.28 billion CNY, reflecting an 8.74% year-on-year increase [4] - The net profit attributable to shareholders was approximately 189.17 million CNY, a decrease of 6.57% compared to the previous year [4][5] - The company’s cumulative undistributed profits as of December 31, 2024, amounted to 561.12 million CNY [1][3] R&D Investment - The company has increased its R&D investment to approximately 311.79 million CNY, a 25.42% increase year-on-year, representing 24.31% of its revenue [5][6] - The R&D investment for innovative drugs and inhalation formulations accounted for 62.78% of total R&D spending, with significant year-on-year growth [6][7] Business Strategy and Development - The company focuses on high-tech pharmaceutical manufacturing, emphasizing innovation in generic drugs, complex formulations, and original new drugs [4][5] - The company is in a critical growth phase, requiring substantial funding for R&D and operational needs, which will be supported by retained earnings and other financing channels [4][6] Shareholder Engagement - The company has implemented measures to facilitate shareholder participation in the cash dividend decision-making process, including in-person and online voting options for the annual general meeting [6][7]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-006 博瑞生物医药（苏州）股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 博瑞生物医药（苏州）股份有限公司（以下简称"公司"或"博瑞医药"） 第四届监事会第四次会议于 2025 年 4 月 1 日以现场会议加通讯表决方式在 C27 栋会议室召开。本次会议通知以及相关材料已于 2025 年 3 月 22 日以邮件方式送 达公司全体监事。 本次会议应出席监事 5 名，实到 5 名，会议由何幸先生召集。本次会议的召 集、召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规 定。 二、监事会会议审议情况 （一）审议通过《2024 年监事会工作报告》 表决结果：5 票同意；0 票反对；0 票弃权。 本议案尚需提交公司 2024 年年度股东大会审议。 （二）审议通过《2024 年年度报告及摘要》 监事会认为：公司 2024 年年度报告的编制和审议程序符合法律法规和《公 司章程》的规定。报告内容真实、准确、完整的反映了公 ...